Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis

One third of the world is infected with Mycobacterium tuberculosis (Mtb) with eight million new cases of active tuberculosis (TB) each year. Development of a new vaccine to augment or replace the only approved TB vaccine, BCG, is needed to control this disease. Mtb infection is primarily controlled...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Orr, Mark T., Fox, Christopher B., Baldwin, Susan L., Sivananthan, Sandra J., Lucas, Elyse, Lin, Susan, Phan, Tony, Moon, James J., Vedvick, Thomas S., Reed, Steven G., Coler, Rhea N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3871206/
https://ncbi.nlm.nih.gov/pubmed/23933525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2013.07.030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados